Details of Disease

General Information of Disease (ID: DISYBB1W)

• Disease Name: Thyroid gland undifferentiated (anaplastic) carcinoma
• Synonyms: THAP; thyroid cancer, anaplastic; thyroid carcinoma, anaplastic; sarcomatoid thyroid gland carcinoma; undifferentiated carcinoma of thyroid; undifferentiated thyroid gland carcinoma; anaplastic carcinoma of the thyroid gland; undifferentiated thyroid tumour; undifferentiated thyroid carcinoma; anaplastic thyroid carcinoma; metaplastic thyroid gland carcinoma; undifferentiated thyroid tumor; undifferentiated carcinoma of the thyroid; anaplastic carcinoma of thyroid; undifferentiated carcinoma of the thyroid gland; Dedifferentiated thyroid gland carcinoma; undifferentiated (anaplastic) thyroid gland carcinoma; undifferentiated carcinoma of thyroid gland; anaplastic carcinoma of the thyroid; thyroid gland carcinosarcoma; anaplastic carcinoma of thyroid gland; anaplastic thyroid cancer; pleomorphic thyroid gland carcinoma; undifferentiated (anaplastic) thyroid gland cancer; thyroid gland undifferentiated carcinoma; thyroid gland undifferentiated (anaplastic) carcinoma; anaplastic thyroid gland carcinoma
• Definition: A primary carcinoma of the thyroid gland composed of undifferentiated cells. The malignant cells demonstrate evidence of epithelial differentiation, either by immunohistochemistry or electron microscopic studies. Microscopically, in the majority of cases there is a mixture of spindle, epithelioid, and giant cells. The vast majority of the patients present with a rapidly enlarging neck mass. The clinical course is usually aggressive.
• Disease Hierarchy:
  DISMNGZ0: Thyroid gland carcinoma
  DISYMCOF: Large cell carcinoma
  DISIAZST: Undifferentiated carcinoma
  DISYBB1W: Thyroid gland undifferentiated (anaplastic) carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0006468
  MESH ID: D065646
  UMLS CUI: C0238461
  MedGen ID: 116064
  HPO ID: HP:0011779
  Orphanet ID: 142
  SNOMED CT ID: 255031003

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 29 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
S1PR2	TTVSMOH	Limited	Biomarker	[1]
KLB	TTARBVH	Disputed	Biomarker	[2]
SIK1	TT1H6LC	Disputed	Genetic Variation	[3]
GAA	TTLPC70	moderate	Genetic Variation	[4]
MAPKAP1	TTWDKCL	moderate	Altered Expression	[5]
SSTR1	TTIND6G	moderate	Altered Expression	[6]
SSTR5	TT2BC4G	moderate	Altered Expression	[6]
TPCN1	TTODQE2	moderate	Biomarker	[7]
ALK	TTPMQSO	Strong	Genetic Variation	[8]
CBX7	TTBN3HC	Strong	Altered Expression	[9]
CD274	TT8ZLTI	Strong	Biomarker	[10]
CDK12	TTJ21A9	Strong	Biomarker	[11]
CYP19A1	TTSZLWK	Strong	Biomarker	[12]
ESRRG	TT9ZRHB	Strong	Altered Expression	[13]
FDPS	TTIKWV4	Strong	Biomarker	[14]
FES	TTLBY21	Strong	Biomarker	[14]
ITCH	TT5SEWD	Strong	Altered Expression	[15]
LGALS3	TTFPQV7	Strong	Altered Expression	[16]
NCOA4	TT8OY02	Strong	Biomarker	[17]
OGFR	TT6IEYX	Strong	Biomarker	[18]
PGD	TTZ3IFB	Strong	Biomarker	[19]
RXFP1	TTMAHD1	Strong	Biomarker	[20]
SLC5A5	TTW7HI9	Strong	Biomarker	[13]
SLC7A5	TTPH2JB	Strong	Altered Expression	[21]
TIGIT	TTWNL74	Strong	Biomarker	[22]
TKT	TT04R7I	Strong	Biomarker	[23]
TPO	TT52XDZ	Strong	Biomarker	[24]
TSHR	TT6NYJA	Strong	Genetic Variation	[25]
F11R	TT3C8EG	Definitive	Altered Expression	[26]

This Disease Is Related to 67 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CLC	OTYMYR85	Limited	Genetic Variation	[27]
DCT	OTYVNTBG	Limited	Biomarker	[28]
FUCA1	OTW71IK4	Limited	Altered Expression	[29]
GDF1	OTZ1VRBH	Limited	Genetic Variation	[30]
MMUT	OTBBBV70	Limited	Altered Expression	[31]
RNH1	OT6EC79B	Limited	Genetic Variation	[30]
SHC3	OT305NPA	Limited	Genetic Variation	[30]
SPC24	OT1HVYV4	Limited	Biomarker	[32]
STRN	OTLOZL5I	Limited	Genetic Variation	[33]
IMPACT	OTQ923OB	Disputed	Genetic Variation	[3]
TRIM8	OTS6JFR0	Disputed	Biomarker	[34]
GLYAT	OT3WWYXD	moderate	Genetic Variation	[4]
AMFR	OTQRX7LC	Strong	Altered Expression	[35]
BCKDHB	OT8OSVYU	Strong	Biomarker	[36]
CCDC80	OTOZSYEM	Strong	Altered Expression	[37]
CCL28	OTY6XNQ7	Strong	Biomarker	[38]
CCNA1	OTX4HD45	Strong	Biomarker	[39]
CRABP2	OTY01V9G	Strong	Altered Expression	[40]
DIS3L2	OTWABM04	Strong	Genetic Variation	[41]
DOCK3	OTF3YS2W	Strong	Altered Expression	[14]
DUSP26	OTI7WIYN	Strong	Biomarker	[42]
ECRG4	OTHZYUXX	Strong	Biomarker	[43]
EIF1AX	OTWG2LAB	Strong	Genetic Variation	[44]
FBLIM1	OTFHXMON	Strong	Biomarker	[45]
FOXA1	OTEBY0TD	Strong	Biomarker	[46]
FOXD3	OTXYV6GO	Strong	Altered Expression	[47]
FOXE1	OT5IR5IT	Strong	Biomarker	[43]
GADD45G	OT8V1J4M	Strong	Biomarker	[48]
GOPC	OTRBGH71	Strong	Biomarker	[45]
GOT2	OT6XBWN0	Strong	Biomarker	[49]
INO80	OTJBMS8T	Strong	Biomarker	[50]
INSL3	OT7KUNTE	Strong	Altered Expression	[51]
IYD	OT8BQWTE	Strong	Altered Expression	[52]
KATNB1	OT7CLZKS	Strong	Genetic Variation	[53]
LAT	OTZC1XZ1	Strong	Altered Expression	[21]
MADD	OTUFYVGG	Strong	Biomarker	[54]
MAFK	OTZJUE4P	Strong	Biomarker	[43]
MCM5	OTAHLB62	Strong	Biomarker	[55]
MED1	OTOO24C4	Strong	Altered Expression	[14]
MRO	OT5U38CP	Strong	Biomarker	[56]
NFYB	OTXSE7KW	Strong	Biomarker	[57]
PARD3	OTH5BPLO	Strong	Biomarker	[58]
PATZ1	OT0X9WGR	Strong	Altered Expression	[59]
PAX8	OTRPD9MI	Strong	Altered Expression	[60]
PJA2	OT45TMC4	Strong	Altered Expression	[61]
PSME3	OTSTC4YY	Strong	Biomarker	[62]
RAP2A	OT0JB5S4	Strong	Altered Expression	[63]
RASAL1	OTAHUNN7	Strong	Genetic Variation	[64]
RXFP2	OT7SAT9U	Strong	Altered Expression	[51]
RYBP	OTZZ4P2Z	Strong	Biomarker	[65]
SFXN1	OTL66767	Strong	Biomarker	[66]
SPAG5	OTCLJ56M	Strong	Altered Expression	[67]
SPAG9	OT45AHMB	Strong	Altered Expression	[67]
TAF1	OTDYS5G4	Strong	Biomarker	[49]
TCEAL4	OTX24CQI	Strong	Biomarker	[68]
TCP1	OT1MGUX9	Strong	Biomarker	[69]
TFCP2L1	OT7QIJ0X	Strong	Altered Expression	[70]
TG	OT3ELHIJ	Strong	Altered Expression	[71]
THY1	OTVONVTB	Strong	Biomarker	[72]
TIA1	OTGPN3P8	Strong	Altered Expression	[73]
TMEM184C	OTCA2HUW	Strong	Biomarker	[74]
TRAF3IP2	OTLLZERL	Strong	Biomarker	[69]
TSTD1	OT5DMKFX	Strong	Genetic Variation	[53]
TTF1	OT4K90WD	Strong	Altered Expression	[75]
BRMS1	OTV5A6LL	Definitive	Altered Expression	[76]
HCP5	OTV0YRI8	Definitive	Altered Expression	[77]
RAP1GAP	OTC31ONQ	Definitive	Altered Expression	[63]

References

• [1] Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2.PLoS One. 2018 May 7;13(5):e0196992. doi: 10.1371/journal.pone.0196992. eCollection 2018.
• [2] Alteration in the serum concentrations of FGF19, FGFR4 and Klotho in patients with thyroid cancer.Cytokine. 2018 May;105:32-36. doi: 10.1016/j.cyto.2018.02.013. Epub 2018 Feb 10.
• [3] Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. doi: 10.1158/1078-0432.CCR-18-0373. Epub 2018 Apr 3.
• [4] Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.Cancer Res. 1997 Sep 1;57(17):3772-8.
• [5] SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.Surgery. 2014 Dec;156(6):1542-8; discussion 1548-9. doi: 10.1016/j.surg.2014.08.095. Epub 2014 Nov 11.
• [6] Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers.Surgery. 2019 Jan;165(1):64-68. doi: 10.1016/j.surg.2018.05.077. Epub 2018 Nov 8.
• [7] Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer.Mol Cell Endocrinol. 2016 Aug 15;431:36-45. doi: 10.1016/j.mce.2016.05.002. Epub 2016 May 3.
• [8] Increased Anaplastic Lymphoma Kinase Activity Induces a Poorly Differentiated Thyroid Carcinoma in Mice.Thyroid. 2019 Oct;29(10):1438-1446. doi: 10.1089/thy.2018.0526. Epub 2019 Oct 8.
• [9] Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.Cancer Res. 2009 Sep 1;69(17):7079-87. doi: 10.1158/0008-5472.CAN-09-1542. Epub 2009 Aug 25.
• [10] Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.Endocrine. 2019 Apr;64(1):122-129. doi: 10.1007/s12020-019-01865-5. Epub 2019 Feb 14.
• [11] Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.Biochem Biophys Res Commun. 2019 Dec 10;520(3):544-550. doi: 10.1016/j.bbrc.2019.10.052. Epub 2019 Oct 12.
• [12] miR-206 inhibits metastasis-relevant traits by degrading MRTF-A in anaplastic thyroid cancer.Int J Oncol. 2015 Jul;47(1):133-42. doi: 10.3892/ijo.2015.2993. Epub 2015 May 8.
• [13] A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERR), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer.Clin Cancer Res. 2019 Aug 15;25(16):5069-5081. doi: 10.1158/1078-0432.CCR-18-3007. Epub 2019 Apr 22.
• [14] Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes.Endocr Relat Cancer. 2004 Dec;11(4):843-54. doi: 10.1677/erc.1.00818.
• [15] ITCH is a putative target for a novel 20q11.22 amplification detected in anaplastic thyroid carcinoma cells by array-based comparative genomic hybridization.Cancer Sci. 2008 Oct;99(10):1940-9. doi: 10.1111/j.1349-7006.2008.00900.x.
• [16] Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer.J Nucl Med. 2019 Jun;60(6):770-776. doi: 10.2967/jnumed.118.219105. Epub 2018 Oct 25.
• [17] High prevalence of RET proto-oncogene activation (RET/PTC) in papillary thyroid carcinomas.Eur J Endocrinol. 2002 Dec;147(6):741-5. doi: 10.1530/eje.0.1470741.
• [18] Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.BMC Cancer. 2009 Oct 18;9:369. doi: 10.1186/1471-2407-9-369.
• [19] Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.Biochem Biophys Res Commun. 2018 Apr 15;498(4):912-917. doi: 10.1016/j.bbrc.2018.03.079. Epub 2018 Mar 14.
• [20] Relaxin enhances the oncogenic potential of human thyroid carcinoma cells.Am J Pathol. 2006 Aug;169(2):617-32. doi: 10.2353/ajpath.2006.050876.
• [21] A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.Sci Rep. 2019 Oct 10;9(1):14616. doi: 10.1038/s41598-019-51144-6.
• [22] Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.J Clin Endocrinol Metab. 2019 Aug 1;104(8):3557-3575. doi: 10.1210/jc.2018-01167.
• [23] Dual effects for lovastatin in anaplastic thyroid cancer: the pivotal effect of transketolase (TKT) on lovastatin and tumor proliferation.J Investig Med. 2018 Jun;66(5):1-9. doi: 10.1136/jim-2017-000634. Epub 2018 Mar 2.
• [24] Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53.Cancer Res. 1996 Feb 15;56(4):765-71.
• [25] Gene rearrangement and Chernobyl related thyroid cancers.Br J Cancer. 2000 Jan;82(2):315-22. doi: 10.1054/bjoc.1999.0921.
• [26] Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 / pathways.Mol Carcinog. 2019 Jul;58(7):1181-1193. doi: 10.1002/mc.23001. Epub 2019 Mar 4.
• [27] NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.Oncotarget. 2017 Jun 27;8(26):42613-42620. doi: 10.18632/oncotarget.17300.
• [28] Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics.Front Endocrinol (Lausanne). 2017 Oct 20;8:277. doi: 10.3389/fendo.2017.00277. eCollection 2017.
• [29] Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.Oncotarget. 2017 Apr 18;8(16):27075-27092. doi: 10.18632/oncotarget.15635.
• [30] Targeted Therapy in Thyroid Cancer: State of the Art.Clin Oncol (R Coll Radiol). 2017 May;29(5):316-324. doi: 10.1016/j.clon.2017.02.009. Epub 2017 Mar 17.
• [31] Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma.J Clin Endocrinol Metab. 2005 Aug;90(8):4703-9. doi: 10.1210/jc.2004-2459. Epub 2005 May 17.
• [32] SPC24 Regulates breast cancer progression by PI3K/AKT signaling.Gene. 2018 Oct 30;675:272-277. doi: 10.1016/j.gene.2018.07.017. Epub 2018 Jul 6.
• [33] Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.Am J Pathol. 2018 Nov;188(11):2653-2661. doi: 10.1016/j.ajpath.2018.07.012. Epub 2018 Aug 18.
• [34] miR-182 promotes tumor growth and increases chemoresistance of human anaplastic thyroid cancer by targeting tripartite motif 8.Onco Targets Ther. 2017 Feb 24;10:1115-1122. doi: 10.2147/OTT.S110468. eCollection 2017.
• [35] Expression of Gp78/Autocrine Motility Factor Receptor and Endocytosis of Autocrine Motility Factor in Human Thyroid Cancer Cells.Cureus. 2019 Jun 17;11(6):e4928. doi: 10.7759/cureus.4928.
• [36] ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.J Clin Endocrinol Metab. 2002 Jun;87(6):2525-31. doi: 10.1210/jcem.87.6.8529.
• [37] Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.J Clin Endocrinol Metab. 2013 Jul;98(7):2834-43. doi: 10.1210/jc.2012-2926. Epub 2013 May 10.
• [38] Bioinformatics analysis of key genes and latent pathway interactions based on the anaplastic thyroid carcinoma gene expression profile.Oncol Lett. 2017 Jan;13(1):167-176. doi: 10.3892/ol.2016.5447. Epub 2016 Nov 30.
• [39] A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.Cancer Lett. 2018 Mar 28;417:131-140. doi: 10.1016/j.canlet.2017.12.037. Epub 2018 Jan 4.
• [40] Resveratrol Reverses Retinoic Acid Resistance of Anaplastic Thyroid Cancer Cells via Demethylating CRABP2 Gene.Front Endocrinol (Lausanne). 2019 Oct 29;10:734. doi: 10.3389/fendo.2019.00734. eCollection 2019.
• [41] Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.Endocrine. 2019 Nov;66(2):288-300. doi: 10.1007/s12020-019-02009-5. Epub 2019 Jul 31.
• [42] A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.Oncogene. 2007 Feb 22;26(8):1178-87. doi: 10.1038/sj.onc.1209899. Epub 2006 Aug 21.
• [43] Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.Thyroid. 2017 Feb;27(2):236-252. doi: 10.1089/thy.2016.0285. Epub 2016 Dec 15.
• [44] The role of EIF1AX in thyroid cancer tumourigenesis and progression.J Endocrinol Invest. 2019 Mar;42(3):313-318. doi: 10.1007/s40618-018-0919-8. Epub 2018 Jul 2.
• [45] Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft.Mol Cancer Ther. 2018 Jun;17(6):1187-1195. doi: 10.1158/1535-7163.MCT-17-0559. Epub 2018 Mar 21.
• [46] Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.Cancer Biol Ther. 2019;20(11):1355-1365. doi: 10.1080/15384047.2019.1617567. Epub 2019 Sep 10.
• [47] FOXD3 regulates anaplastic thyroid cancer progression.Oncotarget. 2017 May 16;8(20):33644-33651. doi: 10.18632/oncotarget.16853.
• [48] Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis.J Clin Endocrinol Metab. 2003 Aug;88(8):3913-20. doi: 10.1210/jc.2002-022031.
• [49] Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.Clin Cancer Res. 2008 Mar 1;14(5):1519-28. doi: 10.1158/1078-0432.CCR-07-4628.
• [50] miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.Oncol Rep. 2016 Dec;36(6):3387-3396. doi: 10.3892/or.2016.5203. Epub 2016 Oct 25.
• [51] INSL-3 is expressed in human hyperplastic and neoplastic thyrocytes.Int J Oncol. 2003 May;22(5):993-1001.
• [52] Characterisation of DEHAL1 expression in thyroid pathologies.Eur J Endocrinol. 2007 Mar;156(3):295-301. doi: 10.1530/EJE-06-0596.
• [53] Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells.Mol Cancer Res. 2009 Oct;7(10):1645-54. doi: 10.1158/1541-7786.MCR-09-0117. Epub 2009 Oct 13.
• [54] Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.Cell Death Dis. 2019 Feb 13;10(2):145. doi: 10.1038/s41419-019-1351-5.
• [55] MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr Relat Cancer. 2016 Apr;23(4):335-47. doi: 10.1530/ERC-15-0322. Epub 2016 Feb 24.
• [56] Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines.J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62. doi: 10.1210/jcem.82.6.4013.
• [57] Integrated Bioinformatics Analysis of Master Regulators in Anaplastic Thyroid Carcinoma.Biomed Res Int. 2019 Apr 28;2019:9734576. doi: 10.1155/2019/9734576. eCollection 2019.
• [58] MicroRNA 483-3p targets Pard3 to potentiate TGF-1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.Oncogene. 2019 Jan;38(5):699-715. doi: 10.1038/s41388-018-0447-1. Epub 2018 Aug 31.
• [59] PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.Oncotarget. 2015 Mar 10;6(7):5310-23. doi: 10.18632/oncotarget.2776.
• [60] PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50.Virchows Arch. 2020 Mar;476(3):431-437. doi: 10.1007/s00428-019-02708-4. Epub 2019 Nov 16.
• [61] Expression of the ring ligase PRAJA2 in thyroid cancer.J Clin Endocrinol Metab. 2012 Nov;97(11):4253-9. doi: 10.1210/jc.2012-2360. Epub 2012 Sep 4.
• [62] REG ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF- pathway.Cell Death Differ. 2020 Feb;27(2):497-508. doi: 10.1038/s41418-019-0367-9. Epub 2019 Jun 26.
• [63] RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.Endocr Relat Cancer. 2012 Jul 22;19(4):575-88. doi: 10.1530/ERC-12-0086. Print 2012 Aug.
• [64] Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.Thyroid. 2016 May;26(5):683-90. doi: 10.1089/thy.2015.0506. Epub 2016 Apr 13.
• [65] Overexpression of RYBP inhibits proliferation, invasion, and chemoresistance to cisplatin in anaplastic thyroid cancer cells via the EGFR pathway.J Biochem Mol Toxicol. 2019 Feb;33(2):e22241. doi: 10.1002/jbt.22241. Epub 2018 Nov 15.
• [66] Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073.
• [67] LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR??p and regulating SPAG9 expression.Int J Oncol. 2019 Nov;55(5):988-1002. doi: 10.3892/ijo.2019.4868. Epub 2019 Sep 4.
• [68] Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.BMC Cancer. 2006 Nov 1;6:260. doi: 10.1186/1471-2407-6-260.
• [69] Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer.J Pathol. 2012 Sep;228(1):56-66. doi: 10.1002/path.4041. Epub 2012 Jul 10.
• [70] Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing.Cell Stress Chaperones. 2005 Autumn;10(3):171-84. doi: 10.1379/csc-107r.1.
• [71] Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.J Nucl Med. 2018 May;59(5):780-786. doi: 10.2967/jnumed.117.200675. Epub 2017 Dec 14.
• [72] Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells.Anticancer Agents Med Chem. 2019;19(15):1887-1898. doi: 10.2174/1871520619666191004144025.
• [73] MiR-599 serves a suppressive role in anaplastic thyroid cancer by activating the T-cell intracellular antigen.Exp Ther Med. 2019 Oct;18(4):2413-2420. doi: 10.3892/etm.2019.7864. Epub 2019 Aug 7.
• [74] Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.J Cancer Res Clin Oncol. 2007 Apr;133(4):213-8. doi: 10.1007/s00432-006-0159-8. Epub 2006 Oct 28.
• [75] Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death.J Clin Med. 2018 Mar 21;7(4):61. doi: 10.3390/jcm7040061.
• [76] BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients.Onco Targets Ther. 2019 Aug 28;12:6937-6945. doi: 10.2147/OTT.S219506. eCollection 2019.
• [77] Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.Biomed Pharmacother. 2019 Aug;116:108966. doi: 10.1016/j.biopha.2019.108966. Epub 2019 May 16.